The MFDS has announced that it will establish a new indicator that eases the phase 3 clinical criteria for the existing COVID-19.

Through this, the plan is to support the rapid commercialization of domestically developed vaccines.

Director Kang-rip Kim made such a statement at a briefing at the special quarantine inspection meeting in response to COVID-19 on the 12th.

Director Kim said, "We will promote the rapid establishment of immune surrogate indicators that enable clinical trials at low cost and with a smaller number of subjects compared to the existing phase 3 clinical trials," and "guide for vaccine development using immune surrogate indicators. We will coop